10-K: Guided Therapeutics Faces Going Concern Uncertainty Despite Efforts to Secure FDA Approval and Expand Internationally

Guided Therapeutics' 10-K filing reveals ongoing financial challenges and efforts to commercialize its LuViva cervical cancer detection device while pursuing regulatory approvals and strategic partnerships.

Summary

• Guided Therapeutics, Inc., a medical technology company, is focused on developing and marketing its LuViva Advanced Cervical Scan device.
• The company's primary focus is on sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device.
• The company faces significant financial challenges, including recurring losses and an accumulated deficit of $153.7 million as of December 31, 2024.
• The independent registered public accounting firm's report indicates substantial doubt about the company's ability to continue as a going concern.
• Guided Therapeutics is pursuing regulatory approval for LuViva in the United States, China, and Europe.
• A clinical trial is underway in the U.S. to support FDA approval, with approximately 320 patients enrolled out of the planned 400.
• The company's Chinese partner, SMI, filed for NMPA approval on October 16, 2024, and believes approval could occur in the second quarter of 2025.
• The company is managing the development of other programs only when funds are made available to us via grants or contracts with government entities or strategic partners.
• The company had cash of approximately $0.4 million and negative working capital of $4.9 million as of December 31, 2024.
• The company estimates that approximately $2.5 million will be needed to fund the business over the next 12 months.
• The company is managing the development of other programs only when funds are made available to us via grants or contracts with government entities or strategic partners.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with a high degree of uncertainty regarding the company's future viability. While there are positive aspects such as ongoing clinical trials and regulatory efforts, the overall tone is negative due to the significant financial risks and the auditor's going concern warning.

Positives

• The company is actively pursuing FDA approval in the U.S. and NMPA approval in China.
• The company has legitimate pathways for securing marketing approvals in the two largest medical markets the US and China, within a 1-2 year period.
• The clinical results of our technology have been published in leading peer-reviewed journals by world famous, thought leading physicians.
• The engineering and production risks have been largely addressed as we have sold 148 working systems worldwide.
• Regulatory approvals have been granted covering over 40 countries.
• The company has a deferred revenue balance of $848,917, which will be recognized as revenue when our products are shipped.
• The company has a history of losses, and we expect losses to continue.

Negatives

• The company faces substantial financial challenges, with an accumulated deficit of $153.7 million as of December 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company had cash of approximately $0.4 million and negative working capital of $4.9 million as of December 31, 2024.
• The company estimates that approximately $2.5 million will be needed to fund the business over the next 12 months.
• The company has a history of losses, and we expect losses to continue.
• The company currently holds $1.13 million of senior unsecured convertible debentures that are in default, which may further hinder our ability to obtain additional debt funding.

Risks

• The company's independent auditor has raised substantial doubt about its ability to continue as a going concern.
• The company will be required to raise additional funds, and there is no assurance that such funds can be raised on terms that we would find acceptable, on a timely basis, or at all.
• The company's ability to sell its products is controlled by government regulations, and we may not be able to obtain any necessary clearances or approvals.
• The company depends on a limited number of distributors and any reduction, delay or cancellation of an order from these distributors or the loss of any of these distributors could cause our revenue to decline.
• The company's success largely depends on our ability to maintain and protect the proprietary information on which we base our products.
• The company may not be able to generate sufficient sales revenues to sustain our growth and strategy plans.
• The company has limited manufacturing experience, which could limit our growth.
• The company has a substantial amount of indebtedness, which may adversely affect our cash flow and our ability to operate our business.
• The company's success depends on our ability to attract and retain scientific, technical, managerial and finance personnel.
• The market prices for our common stock are volatile and will fluctuate.
• There is a limited market for our securities.
• Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.
• Future sales of common stock by officers and directors may negatively impact the market price for our common stock.
• We do not currently pay dividends on our common stock and have no intention to pay dividends on our common stock for the foreseeable future.
• In connection with the audits of our financial statements as of and for the years ended December 31, 2024 and 2023, material weaknesses in our internal control over financial reporting were identified and we may identify additional material weaknesses in the future.
• Anti-takeover provisions in our Amended and Restated Certificate of Incorporation and By-laws may reduce the likelihood of a potential change of control, or make it more difficult for our stockholders to replace management.
• If securities or industry analysts publish inaccurate or unfavorable research about our business, our share price and trading volume may decline.
• The number of shares of our common stock issuable upon the conversion of our outstanding convertible debt and preferred stock or exercise of outstanding warrants and options is substantial.
• Our need to raise additional capital in the near future or to use our equity securities for payments could have a dilutive effect on your investment.
• Common stockholders are subordinated to our lenders.

Future Outlook

The company plans to seek FDA approval in the U.S., NMPA approval in China, and pursue regulatory approval in Russia while selectively supporting sales through distributors in other countries.

Management Comments

• Management believes that additional financing, if obtainable, will be sufficient to support planned operations only for a limited period.
• Management has implemented operating actions to reduce cash requirements.

Industry Context

The medical device industry, particularly the market for cervical cancer detection, is intensely competitive, with established players and emerging technologies vying for market share.

Comparison to Industry Standards

• The Pap test, HPV test, and colposcopy are well-established methods for cervical cancer screening and diagnosis.
• Competitors include Hologic (ThinPrep), Qiagen (HPV testing), Spectrascience, Dysis, and Zedco.
• Roche's cobas HPV test is a primary screener for cervical cancer.
• Merck's Gardasil and GlaxoSmithKline's Cervarix are HPV vaccines for cervical cancer prevention.

Management Changes

Related Party Transactions

• The company has entered into various agreements with related parties, including directors and officers, for consulting services, debt exchanges, and stock issuances.
• The company issued promissory notes totaling $75,000 to members of the Board of Directors.
• The company entered into an exchange agreement with a former employee, whereby the former employee agreed to exchange outstanding amounts due to him for deferred compensation in the amount of $81,768 for an $87,162 promissory note dated April 15, 2024.
• The company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years.
• The company entered into a consulting agreement with Richard Blumberg.

Stakeholder Impact

• Shareholders face significant risk of dilution and potential loss of investment.
• Employees face uncertainty regarding job security due to the company's financial instability.
• Customers and distributors face uncertainty regarding the company's ability to continue supplying products and services.
• Creditors face risk of non-payment due to the company's financial difficulties.

Next Steps

• Seek US FDA approval by completing a clinical trial.
• Seek Chinese FDA approval working with our existing partner in China, Shandong Medical Instrumentation Co. Ltd.
• Pursue regulatory approval in Russia and work with our partner in Central and Eastern Europe, Newmars Technology, Inc. to generate sales in central and eastern Europe.
• Continue to selectively support sales through our distributors in large countries such as Indonesia.

Key Dates

Keywords

LuViva, cervical cancer, medical device, regulatory approval, biophotonics, FDA, NMPA, clinical trial, financial results, going concern, convertible debt, warrants, preferred stock, dilution, risk factors, OTC Markets, GTHP